US › Healthcare

Scinai Immunotherapeutics Ltd (SCNI)

US · Healthcare · Biotechnology

$0.25-8.35%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$487,674

Revenue YoY

+136.7%

Net profit

$3.6M

Profit YoY

+260.0%

EPS

$0.94

Net margin

731.5%

Key statistics

Market cap

$1.4M

P/E

0.2

Forward P/E

0.0

P/B

0.22

Book value

$1.74

EPS (TTM)

$1.75

52-week high

$1.97

52-week low

$0.21

50-day MA

$0.32

200-day MA

$0.73

Beta

2.11

Analyst view

Analysts rate Scinai Immunotherapeutics Ltd a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $700.00.

Shareholding

Institutions

1.58%

Largest institutional holders

Fund	Stake
XTX Topco Ltd	0.61%
Rhumbline Advisers	0.05%
UBS Group AG	0.02%
Morgan Stanley - Brokerage Accounts	0.00%
Virtu Financial LLC	0.00%
Citadel Advisors Llc	0.00%
Northwestern Mutual Wealth Management Co	0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Scinai Immunotherapeutics Ltd — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.